Abstract
Congenital Disorders of Glycosylation (CDG) are a rapidly growing family of genetic and mostly multisystem diseases caused by defects in the biosynthesis of the glycan moiety of glycoconjugates such as glycoproteins. Since the description of the first patients by Jaeken et al. in 1980, 23 defects have been identified in N- and O-protein glycosylation: 18 defects in N- or N- and O-glycosylation (12 glycan assembly defects: CDG-Ia to CDG-IL; 6 glycan processing defects: CDG-IIa to CDG-IIf) and 5 defects in O-glycosylation. There is a rapidly growing number of patients with a putative CDG in whom the known defects have been excluded (CDG-x). This review focuses on recent developments in the field including advances in the biochemical and molecular diagnosis of CDG and new features of known CDG. It also deals with the identification of new protein glycosylation disorders, of the first lipid glycosylation disorder, and of the emerging group of hyperglycosylation disorders. Finally, we speculate about future developments.
Keywords: CDG, COG, hyperglycosylation, lipid glycosylation, protein glycosylation
Current Pediatric Reviews
Title: Congenital Disorders of Glycosylation (CDG): Update and Perspectives
Volume: 2 Issue: 4
Author(s): Renate Zeevaert, Els Schollen, Hubert Carchon, Gert Matthijs and Jaak Jaeken
Affiliation:
Keywords: CDG, COG, hyperglycosylation, lipid glycosylation, protein glycosylation
Abstract: Congenital Disorders of Glycosylation (CDG) are a rapidly growing family of genetic and mostly multisystem diseases caused by defects in the biosynthesis of the glycan moiety of glycoconjugates such as glycoproteins. Since the description of the first patients by Jaeken et al. in 1980, 23 defects have been identified in N- and O-protein glycosylation: 18 defects in N- or N- and O-glycosylation (12 glycan assembly defects: CDG-Ia to CDG-IL; 6 glycan processing defects: CDG-IIa to CDG-IIf) and 5 defects in O-glycosylation. There is a rapidly growing number of patients with a putative CDG in whom the known defects have been excluded (CDG-x). This review focuses on recent developments in the field including advances in the biochemical and molecular diagnosis of CDG and new features of known CDG. It also deals with the identification of new protein glycosylation disorders, of the first lipid glycosylation disorder, and of the emerging group of hyperglycosylation disorders. Finally, we speculate about future developments.
Export Options
About this article
Cite this article as:
Zeevaert Renate, Schollen Els, Carchon Hubert, Matthijs Gert and Jaeken Jaak, Congenital Disorders of Glycosylation (CDG): Update and Perspectives, Current Pediatric Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339606778699699
DOI https://dx.doi.org/10.2174/157339606778699699 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B))
Current Pharmaceutical Design Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults
Current Psychiatry Reviews Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death
Current Pharmaceutical Biotechnology Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry